Show simple item record

dc.contributor.authorHerr, Christian
dc.contributor.authorMang, Sebastian
dc.contributor.authorMozafari, Bahareh
dc.contributor.authorGuenther, Katharina
dc.contributor.authorSpeer, Thimoteus
dc.contributor.authorSeibert, Martina
dc.contributor.authorSrikakulam, Sanjay Kumar
dc.contributor.authorBeisswenger, Christoph
dc.contributor.authorRitzmann, Felix
dc.contributor.authorKeller, Andreas
dc.contributor.authorMueller, Rolf
dc.contributor.authorSmola, Sigrun
dc.contributor.authorEisinger, Dominic
dc.contributor.authorZemlin, Michael
dc.contributor.authorDanziger, Guy
dc.contributor.authorVolk, Thomas
dc.contributor.authorHoersch, Sabrina
dc.contributor.authorKrawczyk, Marcin
dc.contributor.authorLammert, Frank
dc.contributor.authorAdams, Thomas
dc.contributor.authorWagenpfeil, Gudrun
dc.contributor.authorKindermann, Michael
dc.contributor.authorMarcu, Constantin
dc.contributor.authorAtaya, Zuhair Wolf Dietrich
dc.contributor.authorMittag, Marc
dc.contributor.authorSchwarzkopf, Konrad
dc.contributor.authorCustodis, Florian
dc.contributor.authorGrandt, Daniel
dc.contributor.authorSchaefer, Harald
dc.contributor.authorEltges, Kai
dc.contributor.authorLepper, Philipp M
dc.contributor.authorBals, Robert
dc.identifier.citationJ Inflamm Res. 2021 Sep 15;14:4651-4667. doi: 10.2147/JIR.S320685.en_US
dc.description.abstractBackground: COVID-19 comprises several severity stages ranging from oligosymptomatic disease to multi-organ failure and fatal outcomes. The mechanisms why COVID-19 is a mild disease in some patients and progresses to a severe multi-organ and often fatal disease with respiratory failure are not known. Biomarkers that predict the course of disease are urgently needed. The aim of this study was to evaluate a large spectrum of established laboratory measurements. Patients and methods: Patients from the prospective PULMPOHOM and CORSAAR studies were recruited and comprised 35 patients with COVID-19, 23 with conventional pneumonia, and 28 control patients undergoing elective non-pulmonary surgery. Venous blood was used to measure the serum concentrations of 79 proteins by Luminex multiplex immunoassay technology. Distribution of biomarkers between groups and association with disease severity and outcomes were analyzed. Results: The biomarker profiles between the three groups differed significantly with elevation of specific proteins specific for the respective conditions. Several biomarkers correlated significantly with disease severity and death. Uniform manifold approximation and projection (UMAP) analysis revealed a significant separation of the three disease groups and separated between survivors and deceased patients. Different models were developed to predict mortality based on the baseline measurements of several protein markers. A score combining IL-1ra, IL-8, IL-10, MCP-1, SCF and CA-9 was associated with significantly higher mortality (AUC 0.929). Discussion: Several newly identified blood markers were significantly increased in patients with severe COVID-19 (AAT, EN-RAGE, myoglobin, SAP, TIMP-1, vWF, decorin) or in patients that died (IL-1ra, IL-8, IL-10, MCP-1, SCF, CA-9). The use of established assay technologies allows for rapid translation into clinical practice.en_US
dc.publisherDove Pressen_US
dc.rightsAttribution 4.0 International*
dc.titleDistinct Patterns of Blood Cytokines Beyond a Cytokine Storm Predict Mortality in COVID-19.en_US
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalJournal of inflammation researchen_US
dc.source.journaltitleJournal of inflammation research
dc.source.countryNew Zealand

Files in this item

Herr et al.pdf
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International